Patents Assigned to Biogen Idec Ma Inc.
  • METHODS OF TREATING CENTRAL NERVOUS SYSTEM ISCHEMIC OR HEMORRHAGIC INJURY USING ANTI ALPHA4 INTEGRIN ANTAGONISTS
    Publication number: 20140127195
    Abstract: Methods of, and compositions for, treating central nervous system injury with an antagonist of an alpha4 subunit containing integrin are described.
    Type: Application
    Filed: January 10, 2014
    Publication date: May 8, 2014
    Applicant: BIOGEN IDEC MA INC.
    Inventors: Jane K. Relton, Roy R. Lobb, Eric T. Whalley, Steve P. Adams
  • Method for increasing expression of active tumor necrosis factor receptor family member-Ig fusion proteins
    Patent number: 8709759
    Abstract: Methods for high level expression of active lymphotoxin-? receptor immunoglobulin chimeric proteins and their purification.
    Type: Grant
    Filed: July 19, 2012
    Date of Patent: April 29, 2014
    Assignee: Biogen Idec MA Inc.
    Inventors: Jeffrey Browning, Konrad Miatkowski, Werner Meier
  • Methods of evaluating BAFF
    Patent number: 8685657
    Abstract: The present disclosure provides compositions and methods relating to the evaluation of BAFF in a biological sample from a subject.
    Type: Grant
    Filed: March 8, 2013
    Date of Patent: April 1, 2014
    Assignee: Biogen Idec MA Inc.
    Inventors: Yen-Ming Hsu, Susan Kalled
  • ANTI-LYMPHOTOXIN ANTIBODIES
    Publication number: 20140079716
    Abstract: The instant invention is based, at least in part on the identification of a new class of antibodies that result, e.g., in improved LT blocking capabilities. Methods of making the subject binding molecules and methods of using the binding molecules of the invention to antagonize LT?R signaling are also provided.
    Type: Application
    Filed: March 14, 2013
    Publication date: March 20, 2014
    Applicant: BIOGEN IDEC MA INC.
    Inventor: BIOGEN IDEC MA INC.
  • LINKER PEPTIDES AND POLYPEPTIDES COMPRISING SAME
    Publication number: 20140079701
    Abstract: The invention is based, at least in part, on the finding that linker peptides which lack the amino acid sequence GSG reduce or eliminate the addition of posttranslational modifications to the polypeptides which comprise them. More specifically, the novel linker peptides disclosed herein reduce the ability of enzymes to link carbohydrate adducts to polypeptides comprising these linker peptides, e.g., reduce the ability of xylosyltransferase to link xylose to polypeptides. These novel linker peptides, molecules comprising same, and methods of their use are described.
    Type: Application
    Filed: December 22, 2011
    Publication date: March 20, 2014
    Applicant: BIOGEN IDEC MA INC.
    Inventors: Brian Robert Miller, Scott Glaser, Justin Caravella, Susan Foley, Xiaoping Hronoeski, Tigran Dikran Alvazian
  • HUMANIZED ANTIBODIES AGAINST MONOCYTE CHEMOTACTIC PROTEINS
    Publication number: 20140079697
    Abstract: The invention provides humanized antibodies that bind to a plurality of b-chemokines, particularly monocyte chemotactic proteins MCP-1, MCP-2 and MCP-3. The invention also provides therapeutic reagents and methods of treating disorders associated with detrimental MCP activity.
    Type: Application
    Filed: July 2, 2013
    Publication date: March 20, 2014
    Applicant: Biogen Idec MA Inc.
    Inventors: Antonin R. DE FOUGEROLLES, Victor E. KOTELIANSKI, Ellen GARBER, Carl REID, Jose W. SALDANHA, Herman VAN VLIJMEN
  • Cripto blocking antibodies and uses thereof
    Patent number: 8673303
    Abstract: The invention provides Cripto blocking antibodies, or biologically functional fragments thereof, and uses thereof. Antibodies which bind Cripto and modulate Cripto signaling are provided. Antibodies which bind Cripto and block the interaction between Cripto and ALK4 are provided. Antibodies which bind Cripto and modulate tumor growth are also provided. Antibodies which bind Cripto, modulate signaling, and modulate tumor growth are also provided. Antibodies which bind Cripto, block the interaction between Cripto and ALK4 and modulate tumor growth are provided. The invention also provides methods of using these antibodies in therapeutic, diagnostic, and research applications.
    Type: Grant
    Filed: August 19, 2011
    Date of Patent: March 18, 2014
    Assignee: Biogen Idec MA Inc.
    Inventors: Michele Sanicola-Nadel, Kevin P. Williams, Susan Gail Schiffer, Paul Rayhorn
  • Nogo receptor antagonists
    Patent number: 8669345
    Abstract: Disclosed are immunogenic Nogo receptor-1 polypeptides, Nogo receptor-1 antibodies, antigen-binding fragments thereof, soluble Nogo receptors and fusion proteins thereof and nucleic acids encoding the same. Also disclosed are Nogo receptor antagonist polynucleotides. Also disclosed are compositions comprising, and methods for making and using, such Nogo receptor antibodies, antigen-binding fragments thereof, soluble Nogo receptors and fusion proteins thereof, nucleic acids encoding the same and antagonist polynucleotides.
    Type: Grant
    Filed: January 26, 2007
    Date of Patent: March 11, 2014
    Assignee: Biogen Idec MA Inc.
    Inventors: Daniel H. S. Lee, Dingyi Wen, R. Blake Pepinsky, Jane K. Relton, Xinzhong Wang, Alexey Lugovskoy, Werner Meier, Ellen A. Garber, Laura Silvian, Paul H. Weinreb
  • Automated System and Method for Monitoring Chromatography Column Performance, and Applications Thereof
    Publication number: 20140067308
    Abstract: The present invention provides automated systems and methods for monitoring column performance in process chromatography, and applications thereof. In an embodiment, column performance is monitored by generating a plurality of process values such as, for example, conductivity values or pH values with a detector during a chromatography step transition between a first mobile phase liquid and a second mobile phase liquid. The process values are transformed to form transformed process values in which noise present in the process values is suppressed. Column performance parameters are calculated based on the transformed process values and displayed during movement of the second mobile phase liquid through the chromatography column.
    Type: Application
    Filed: September 30, 2013
    Publication date: March 6, 2014
    Applicant: Biogen Idec MA Inc.
    Inventors: Paul CUNNIEN, Joydeep GANGULY, Basav GHOSH, Asif LADIWALA, Robert SONG, Jorg THOMMES
  • Anti-CD154 antibodies
    Patent number: 8647625
    Abstract: The present invention provides peptides, and fragments thereof, and antibodies, or fragments thereof comprising the same, wherein the peptide comprises at least one amino acid substitution compared to wild type 5c8 antibody. The present invention also provides compositions and methods of treating CD154-related diseases or disorders in a subject.
    Type: Grant
    Filed: July 26, 2005
    Date of Patent: February 11, 2014
    Assignee: Biogen Idec MA Inc.
    Inventors: Herman Van Vlijmen, Alexey Alexandrovic Lugovskoy, Karl J. M. Hanf
  • Polymer-conjugated glycosylated neublastin
    Patent number: 8642732
    Abstract: The following class of molecule is disclosed: a dimer containing a first neublastin polypeptide and a second neublastin polypeptide, wherein: (a) at least one of the polypeptides is glycosylated; (b) at least one of the polypeptides is conjugated at its N-terminus to a water-soluble synthetic polymer; and (c) neither of the polypeptides is conjugated to a water-soluble synthetic polymer at a position other than the N-terminus. Such dimers possess the biological activity of wild-type neublastin while displaying enhanced serum half-life and enhanced potency relative to wild-type neublastin.
    Type: Grant
    Filed: March 21, 2012
    Date of Patent: February 4, 2014
    Assignee: Biogen Idec MA Inc.
    Inventors: Dinah Wen-Yee Sah, R. Blake Pepinsky, Anthony Rossomando
  • Methods for promoting myelination, neuronal survival and oligodendrocyte differentiation via administration of Sp35 or TrkA antagonists
    Patent number: 8642040
    Abstract: This invention relates to methods for promoting myelination, neuronal survival, and oligodendrocyte differentiation and treating demyelination and dysmyelination disease by the administration of a TrkA antagonist. The invention also relates to methods of inhibiting or decreasing Sp35 expression by the use of a TrkA antagonist. Additionally, the invention relates generally to methods for blocking Sp35 and TrkA interaction and inhibiting or decreasing TrkA phosphorylation by the administration of a Sp35 antagonist.
    Type: Grant
    Filed: July 24, 2007
    Date of Patent: February 4, 2014
    Assignee: Biogen Idec MA Inc.
    Inventors: Sha Mi, Vincent Jung
  • CRIPTO BINDING MOLECULES
    Publication number: 20140017262
    Abstract: The invention pertains to humanized forms of an anti-CRIPTO antibody and portions thereof and their use in treating disorders, such as cancer either alone or in combination with other agents.
    Type: Application
    Filed: March 4, 2013
    Publication date: January 16, 2014
    Applicant: Biogen Idec MA Inc.
    Inventor: Michele SANICOLA-NADEL
  • Use of DR6 and p75 Antagonists to Promote Survival of Cells of the Nervous System
    Publication number: 20140010826
    Abstract: The present invention relates to Death Receptor-6 (DR6) proteins which are members of the tumor necrosis factor (TNF) receptor family, and have now been shown to be important for regulating apoptosis in cells of the nervous system. In addition, it has been discovered that p75 is a ligand for DR6. As a result, this invention relates to methods for inhibiting the interaction of DR6 and p75 using DR6 and/or p75 antagonists. In addition, the methods described herein include methods of promoting survival of cells of the nervous system using DR6 antagonists, optionally in combination with p75 antagonists, and methods of treating neurodegenerative conditions by the administration of a DR6 antagonists, optionally in combination with a p75 antagonist.
    Type: Application
    Filed: July 5, 2013
    Publication date: January 9, 2014
    Applicant: Biogen Idec MA Inc.
    Inventors: Sha MI, Kenneth J. Rhodes, R. Blake Pepinsky
  • Binding molecules and methods of use thereof
    Patent number: 8618042
    Abstract: Binding molecules are described.
    Type: Grant
    Filed: January 25, 2007
    Date of Patent: December 31, 2013
    Assignee: Biogen Idec MA Inc.
    Inventors: Julio H. Cuervo, Russell C. Petter, Daniel Scott, Kathryn Strauch
  • Neonatal Fc receptor (FcRn)-binding polypeptide variants, dimeric Fc binding proteins and methods related thereto
    Patent number: 8618252
    Abstract: The compositions and methods of the present invention are based, in part, on our discovery that an effector function mediated by an Fc-containing polypeptide can be altered by modifying one or more amino acid residues within the polypeptide (by, for example, electrostatic optimization). The polypeptides that can be generated according to the methods of the invention are highly variable, and they can include antibodies and fusion proteins that contain an Fc region or a biologically active portion thereof.
    Type: Grant
    Filed: December 13, 2010
    Date of Patent: December 31, 2013
    Assignee: Biogen Idec MA Inc.
    Inventors: Graham K. Farrington, Alexey Alexandrovich Lugovskoy, Werner Meier, John K. Eldredge, Ellen Garber
  • Methods for use with BAFF antagonists
    Patent number: 8617545
    Abstract: BAFF plays a central role in acquired immunity. The disclosure identifies BAFF-responsive genes that are substantially upregulated by administration of BAFF and substantially downregulated by treatment with a BAFF antagonist. Specific genes are: NF-?B2, CD23, H2-M? (the beta chain of H2-DM), Fig-1, and OBF-1. The disclosure provides methods and compositions for: monitoring the activity of a BAFF antagonist in a mammal; monitoring BAFF activity in a mammal; identifying a mammal to be treated with a BAFF antagonist; and related uses. Such methods include detecting one or more molecules selected from the group consisting of Fig-1 molecule, OBF-1 molecule, and H2-M? molecule in a biological sample of the mammal, and optionally further detecting NF-?B2 molecule and/or CD23 molecule in the biological sample.
    Type: Grant
    Filed: October 12, 2006
    Date of Patent: December 31, 2013
    Assignees: Biogen Idec MA Inc., Genentech, Inc.
    Inventors: Yen-Ming Hsu, Leonid Gorelik, Tatiana Novobrantseva, Joanne Quan, Flavius Martin, Susan L. Kalled
  • HETEROCYCLIC TYROSINE KINASE INHIBITORS
    Publication number: 20130345192
    Abstract: The present invention provides compounds useful as inhibitors of Tec family kinases, compositions thereof, and methods of using the same.
    Type: Application
    Filed: October 28, 2011
    Publication date: December 26, 2013
    Applicants: SUNESIS PHARMACEUTICALS, INC., BIOGEN IDEC MA INC.
    Inventors: Brian T. Hopkins, Daniel Scott, Patrick Conlon, Tracy J. Jenkins, Noel Powell, Bing Guan, Julio H. Cuervo, Deping Wang, Art Taveras
  • Sp35 Antibodies and Uses Thereof
    Publication number: 20130336991
    Abstract: Endogenous Sp35 is a negative regulator for neuronal survival, axon regeneration, oligodendrocyte differentiation and myelination (Negative Regulator). Molecules that block endogenous Sp35 function, such anti-Sp35 antibodies can be used as therapeutics for the treatment of neuron and oligodendrocyte dysfunction. The present invention provides antibodies specific for Sp35, and methods of using such antibodies as antagonists of endogenous Sp35 function. The invention further provides specific hybridoma and phage library-derived monoclonal antibodies, nucleic acids encoding these antibodies, and vectors and host cells comprising these antibodies.
    Type: Application
    Filed: March 15, 2013
    Publication date: December 19, 2013
    Applicant: Biogen Idec MA Inc.
    Inventors: Sha MI, R. Blake PEPINSKY, Zhaohui SHAO, Christilyn GRAFF
  • Compositions and methods for inhibiting growth of SMAD4-deficient cancers
    Patent number: RE44681
    Abstract: The present invention is in the fields of cell biology, immunology and oncology. The invention relates to the discovery that there is a relationship between the expression levels of the tumor suppressor gene smad4 (also known as dpc4) and integrin ???6, and the responsiveness of patient populations to ???6-active compounds and compositions (e.g., antibodies and other ligands that bind ???6), particularly in cancer cells from such patient populations, more particularly on carcinomas such as pancreatic carcinomas.
    Type: Grant
    Filed: April 16, 2013
    Date of Patent: December 31, 2013
    Assignee: Biogen Idec MA Inc.
    Inventors: Shelia M. Violette, Louise A. Koopman